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Abstract
Purpose Anthracyclines cause chronic irreversible cardiac failure, but the mechanism remains poorly understood. Emerging data
indicate that cardiac damage begins early, suggesting protective modalities delivered in the acute stage may confer prolonged
benefit. Ischaemic preconditioning (IPC) activates the pro-survival reperfusion injury salvage kinase (RISK) pathway which
involves PI3-kinase and MAPK/ERK1/2.
Methods We investigated whether simulated IPC (sIPC), in the form of a sublethal exposure to a hypoxic buffer simulating
ischaemic conditions followed by reoxygenation, protects primary adult rat cardiomyocytes against anthracycline-induced injury.
PI3-kinase and MAPK/ERK1/2 were inhibited using LY294002, and PD98059. The role of reactive oxygen species (ROS),
mitochondrial membrane potential (Δψm) and mitochondrial permeability transition pore (mPTP) were also investigated in
doxorubicin-treated cells. We further examined whether sIPC protected HeLa cancer cells from doxorubicin-induced death.
Results sIPC protected cardiomyocytes against doxorubicin-induced death (35.4 ± 1.7% doxorubicin vs 14.7 ± 1.5% doxorubi-
cin + sIPC; p < 0.01). This protection was abrogated by the PI3-kinase inhibitor, LY294002, but not the MAPK/ERK1/2
inhibitor, PD98059. A ROS scavenger failed to rescue cardiomyocytes from doxorubicin toxicity, and no significant influence
on Δψm or mPTP opening was identified after subjecting cells to a doxorubicin insult. Importantly, sIPC did not protect HeLa
cancer cells from doxorubicin-induced death.
Conclusion sIPC is able to protect cardiomyocytes against anthracycline injury via a pathway involving PI3-kinase. This
mechanism appears to be independent of ROS, changes to Δψm, and mPTP. Further investigation of the mechanism of sIPC-
induced protection against anthracycline-injury is warranted.
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Introduction
Anthracyclines, such as doxorubicin, are a group of
anthracenedione antibiotics with cytotoxic potential. They
form an integral part of chemotherapy against a multitude of
cancers, including solid organ tumours, childhood cancers, as
well as haematological malignancies [1]. Unfortunately, the
scope of anthracycline-therapy is significantly limited by
cardiotoxicity. Acutely, this may manifest as transient contrac-
tile dysfunction, inflammatory heart diseases (such as
myocarditis or pericarditis), conduction abnormalities or al-
tered myocardial repolarisation. Chronically, anthracycline-
based chemotherapy can result in irreversible heart failure
manifesting as dilated cardiomyopathy (DCM) and refractory
congestive cardiac failure (CCF). However, emerging data
suggest that cardiac damage begins early and may in fact be
a continuum, implying that the arbitrary division into acute
and chronic damage may be artificial [2]. Cardioprotective
modalities effective against acute injury may therefore provide
prolonged benefit.
The mechanisms of anthracycline-mediated cardiac injury
remain incompletely understood. Reactive oxygen species
(ROS)-mediated oxidative stress, iron-overload mediated tox-
icity, alterations of mitochondrial transmembrane potential
(ΔΨm) and induction of the mitochondrial permeability tran-
sition pore (mPTP) opening have all been postulated to be
involved in the pathological mechanism [3]. However, multi-
ple interventions including ROS-scavenging with N-acetyl
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cysteine (NAC) or iron-chelationwith dexrazoxane have failed
to translate clinically to providing meaningful protection
against cardiotoxicity caused by doxorubicin [4]. Of note how-
ever, doxorubicin has been shown to inhibit a number of pro-
survival signalling cascades. For example, dephosphorylation
of PI3-kinase (PI3K)/Akt after doxorubicin exposure may lead
to activation of apoptotic pathways [5]. Conversely, activation
of PI3K signalling has been demonstrated to ameliorate
doxorubicin-induced cardiomyopathy in vivo [6]. Other exper-
iments have suggested that the MAPK/ERK1/2 pathway can
protect against anthracycline-induced cardiotoxicity [7–9].
It has been known for many years,that brief periods of
ischemia followed by reperfusion can protect the heart against
a subsequent prolonged bout of ischemia. This is known as
ischemic preconditioning (IPC) [10]. A similar phenomenon
can be observed in vitro, by simulating IPC using brief expo-
sure to a hypoxic buffer simulating ischaemic conditions,
followed by reoxygenation. This form of IPC protects
cardiomyocytes against subsequent hypoxic cell death.
Evidence to date implicates a complex kinase signalling cas-
cade in the mechanism of IPC, including activation of PI3-
kinase (PI3K), protein kinase C (PKC) and MAP kinase path-
ways, which are collectively termed the Breperfusion injury
salvage kinase^ (or RISK) pathway [11]. These signalling
pathways converge on mitochondria to protect the
cardiomyocytes by inhibiting opening of the MPTP [10].
Crucially, PI3K inhibition has been shown to abrogate IPC-
mediated protection [12–15].
It has been shown using an isolated, perfused rat heart
model that IPC can prevent some of the loss of function that
occurs when an anthracycline (2mg/ml epirubicin in this case)
is added to the perfusate for 20 min [16]. However, whether
IPC can directly protect cardiomyocytes against anthracycline
toxicity has not been examined. Given the similar pathways of
cardiac injury induced by doxorubicin and ischemia-
reperfusion injury, we investigated the hypothesis that simu-
lated IPC (sIPC) can protect cardiomyocytes against
anthracycline-toxicity in an in vitro model using primary adult
rat cardiomyocytes. It was also important to establish whether
such a cardioprotective modality would protect a cancer cell
line from doxorubicin-induced cell death, for which we used
HeLa cells, a cervical cancer cell line. For these studies, we
chose to use an acute, in vitro model of 18 h doxorubicin
exposure, since doxorubicin toxicity has been shown to occur
early and to be cumulative [17, 18].
Materials and Methods
Animals
Male adult Sprague-Dawley rats (150–450 g weight) were
obtained from UCL biological services unit. All animals were
housed in a temperature-, humidity- and light cycle-controlled
environment. All animal experiments were carried out in ac-
cordance with the UKHomeOffice Guide on the Operation of
Animal (Scientific Procedures) Act of 1986.
Isolation of Ventricular Cardiomyocytes
Ventricular cardiomyocytes were isolated from adult male
Sprague-Dawley rats as described previously [19] but with
omission of heparin whilst administering terminal anaesthesia
with pentobarbital sodium (55 mg/kg) injected i.p. After iso-
lation, cells were cultured in M199 (invitrogen) supplemented
with creatine (5 mM), carnitine (2 mM) and taurine (5 mM)
and streptomycin/penicillin. Cell isolations yielding > 20%
death after 18 h under basal conditions were not used.
Doxorubicin Treatment and Simulated Ischaemic
Preconditioning
Cells were preconditioned by exposing them to hypoxia for
30 min in a buffer simulating tissue ischaemia, followed by
10 min reoxygenation in a buffer simulating reperfusion, prior
to exposure to doxorubicin. Hypoxia was induced in an airtight
hypoxic chamber using a buffer containing 127.8 mM NaCl,
14.8 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 2.2 mM
NaHCO3, 1.0 mM CaCl2 and 10 mM sodium-lactate. The
buffer was gassed with 95% N2/5% CO2 immediately before
use and the pH was adjusted to 6.4 at 37 °C. Reoxygenation
was carried out in a normoxic buffer containing 10 mM glu-
cose, 118 mM NaCl, 1.2 mM KH2PO4, 1.2 mM MgSO4,
22 mM NaHCO3 and 1.0 mM CaCl2, gassed with carbogen
and the pH adjusted at 37 °C to pH 7.4 before use [20].
Preconditioned cardiomyocytes were incubated with the indi-
cated concentrations of doxorubicin for 18 h. Control (non-
preconditioned) cardiomyocytes were incubated in normoxic
buffer for 40 min before replacing the buffer with M199 con-
taining doxorubicin. HeLa cells were treated similarly but
using a concentration of 2 μM doxorubicin since they are
innately more sensitive to doxorubicin.
To investigate the components of the RISK pathway,
cardiomyocytes were subjected to sIPC and doxorubicin in
the presence of 10 μM LY294002 (Sigma Aldrich) to inhibit
PI3K/Akt pathway, or 30 μM PD98059 (Sigma Aldrich) to
inhibit MAPK/ERK1/2, respectively.
Western Blot Analyses
Cells were lysed by boiling in SDS-PAGE sample loading
buffer (1% SDS, 10% glycerol, 10 mM Tris-Cl, pH 6.8,
1 mM EDTA). As positive control for Akt phosphorylation,
cardiomyocytes were treated with 100 nM insulin. The sam-
ples were resolved by SDS-PAGE in 10% acrylamide gel.
Phosphorylated and non-phosphorylated Akt was compared
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to the content of the housekeeping protein glyceraldehyde 3-
phosphate dehydrogenase (GAPDH). To evaluate phosphory-
lation status of MAPK/ ERK1/2, phosphorylated and non-
phosphorylated ERK1/2 was compared to the content of the
housekeeping protein alpha-tubulin.
Primary antibodies used were anti-tAkt (Cell Signaling
Technology, Inc. Cat. no. 2920) anti-pAkt (Phospho-Serine
473, Cell Signalling Technology, Inc. Cat. no. 4060), anti-
tERK1/2 (Cell Signalling Technology, Inc. Cat. no. 9107),
anti- pERK1/2 (Phospho-Threonine 202/Phospho-Tyrosine
204, Cell Signalling Technology, Inc. Cat. no. 4370), anti-
GAPDH (abcam, Cat no. ab9485) and anti-alpha tubulin
(abcam, Cat no. ab4074) All primary antibodies were used
at a dilution of 1:1000. Following overnight incubation, the
membrane was washed and probed with secondary antibodies
using standard Western blot protocol.
Investigation of Reactive Oxygen Species
Cardiomyocytes were incubated with 7.5 μM doxorubicin, in
the presence or absence of N-acetyl cysteine (250 μM NAC,
Thermo Fisher Scient i f ic ) . As posi t ive contro l ,
cardiomyocytes were incubated with 1 μM H2O2 (Sigma-
Aldrich). Cell-death was evaluated at the end of experiment.
Measurement of Mitochondrial Transmembrane
Potential
Cardiomyocytes were cultured in M199 and 7.5 μM doxoru-
bicin added as indicated. Thirty nanomolars tetramethyl rho-
damine methyl ester (TMRM, Thermo Fisher) was added for
30 min in Tyrode’s solution (137 mM NaCl, 2.7 mM KCl,
1 mM MgCl2, 1.8 mM CaCl2, 0.2 mM Na2HPO4, 12 mM
NaHCO3, 5.5 mM D-glucose, pH 7.4), before transferring to
dye-free Tyrode’s solution and analysed by confocal micros-
copy. Transmembrane potential was measured in a Leica SP5
confocal microscope using 10% He-Ne Laser at 543 nm ex-
citation wavelength, and intensity of the emission at 581–
596 nm was recorded. Images were analysed using ImageJ
software.
Measurement of Mitochondrial Permeability Pore
Induction
Cardiomyocytes were incubated with 7.5 μM doxorubicin
dissolved in M199 for 18 h, before loading the cells with
3 μM TMRM in solution in Tyrode’s buffer. The medium
was replaced with dye-free Tyrode’s buffer, and time taken
to mPTP opening determined as described previously [19].
One micromolar cyclosporine A (CsA, Merck Millipore) an
agent known to inhibit pore opening was used as a positive
control.
Assessment of Cell Death
At the end of cell-survival experiments, 5 μg/ml propidium
iodide (PI, Thermo Fisher) was added prior to microscopic
analysis. Representative images were recorded using a
Nikon Eclipse TE200 microscope and analysed using
ImageJ. Cardiomyocyte-death was assessed on the basis of
displaying PI-positive nuclear staining or a terminally dam-
aged morphology [21]. HeLa cell death was based purely on
PI-positive staining.
Statistical Analysis
All data were analysed using Graphpad prism (version 5.0).
Values are expressed as mean ± SEM. Analysis was carried
out using two-way ANOVA, followed by post hoc compari-
son test when significant, using Bonferoni correction for mul-
tiple comparisons. Differences were considered significant if
p values were determined to be p < 0.05. * represents p < 0.05;
** p < 0.01; *** p < 0.001.
Results
Hypoxic Preconditioning Protects Cardiomyocytes
Against Doxorubicin-Induced Injury
We first performed a dose-response experiment to determine
the lethal concentration of 18 h doxorubicin exposure on pri-
mary adult rat cardiomyocytes. After doxorubicin treatment,
cell-death was significantly higher in cells exposed to 7.5 and
10 μM doxorubicin (Fig. 1a). Next, we simulated IPC (sIPC)
in vitro by subjecting the cells to hypoxia and reoxygenation
and determined whether this protected the cells from death.
sIPC prevented doxorubicin from significantly increasing cell
death at both 7.5 and 10 μMdoxorubicin (Con 15.6 ± 1.1% vs
7.5 μM Dox 37 ± 4.9% p < 0.01; Con vs 10 μM Dox 43.1 ±
4.6%, p < 0.001, n = 5) (Fig. 1a). Based on these results, sub-
sequent experiments were carried out using 7.5 μM doxoru-
bicin over a treatment period of 18 h.
We next investigated the role of the RISK pathway in sIPC-
mediated protection against doxorubicin-toxicity. On their
own, LY294002 or PD98059 (antagonists of PI3-kinase and
ERK1/2 respectively) did not affect the levels of cell death in
control cells or those treated with doxorubicin (Fig. 1b). sIPC-
mediated protection against doxorubicin was unaffected by
the presence of the ERK inhibitor, PD98059. However, the
PI3-kinase inhibitor, LY294002, abolished protection by sIPC
(Dox sIPC 16.9 ± 1.5%; Dox sIPC+PD 15.9 ± 1.3%; Dox
sIPC+LY 38.5 ± 3.3%; p < 0.05, n = 5) (Fig. 1b).
Western blot analysis was used to confirm the activation of
the RISK pathway by sIPC in this experimental model. This
confirmed that Akt phosphorylation at Ser 473 was increased
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after sIPC and that phosphorylation was inhibited by
LY294002. Insulin, which strongly activates PI3K kinase ac-
tivity, was used as a positive control for Akt phosphorylation.
Insulin treatment strongly increased Akt phosphorylation
(Fig. 2a). Similarly, phosphorylation of ERK1/2 at Thr 202/
Tyr 204 was observed after treatment with cardiomyocytes
with sIPC (Fig. 2b). Phosphorylation of ERK1/2 was inhibited
in the presence of PD98059 (Fig. 2b).
Doxorubicin-Induced Cardiomyocyte Death Is
Independent of ROS-Production
Part of the mechanism by which IPC is known to protect
cardiomyocytes from ischemia and reperfusion injury is by
limiting ROS production and preventing mPTP opening [19,
22]. We therefore sought to understand the role for ROS and
mitochondria in doxorubicin-induced death. We first exam-
ined whether a ROS scavenger was cardioprotective in our
model of doxorubicin-induced toxicity. Although NAC was
able to protect cardiomyocytes against 1 μM H2O2 (H2O2
43.4 ± 4.5% vs H2O2+NAC 25.3 ± 4%; p < 0.01, n = 3)
(Fig. 3a), it had no effect on doxorubicin-induced cell death
(Dox 40 ± 3.7%; vs Dox NAC 41.4 ± 2.8%; n = 3) (Fig. 3a).
NAC alone did not affect cell-death (Con 16.6 ± 2.7% vs Con
NAC, 18.7 ± 3.7%) (Fig. 3a).
Doxorubicin-Induced Toxicity Is Independent of ΔΨm
and the Induction of the mPTP
We next investigated whether mPTP opening is involved in
doxorubicin-induced cardiomyocyte death in our model. We
used a previously validated, laser-induced toxicity model in
cardiomyocytes, which is based on the photo-oxidation of the
dye TMRM in the mitochondria [23]. Before using thismodel,
we confirmed that the mitochondrial transmembrane potential
(ΔΨm) (and hence mitochondrial TMRM accumulation) was
unchanged in Dox-treated cells (data not shown). We then
investigated whether doxorubicin treatment increases the sen-
sitivity of the mPTP to opening. After 18 h doxorubicin treat-
ment, no significant differences were seen in mPTP sensitiv-
ity, as measured by the time taken until mPTP opening oc-
curred (Dox 842 ± 103 s, vs control 972 ± 74 s, p = 0.4, n = 7)
(Fig. 4a). In a control group, 1 μM CsA (used as a positive
control) protected against mPTP induction in untreated
cardiomyocytes (CsA 1304 ± 111 s, vs Con 901 ± 58 s)
(p < 0.01, n = 7), although it did not protect in cardiomyocytes
subjected to doxorubicin (Fig. 4a).
In order to confirm that prevention of mPTP opening was
not protective against doxorubicin-induced cell death, isolated
cardiomyocytes were subjected for 18 h to 7.5 μM doxorubi-
cin alone or in the presence of 1 μM CsA before evaluating
cell death. CsA failed to protect cardiomyocytes against
doxorubicin-induced cell-death (Dox, 46.9 ± 3.3% vs Dox
CsA 45.3 ± 1.6%, p = 0.9, n = 5) (Fig. 4b).
Preconditioning Does Not Protect a Cancer Cell Line
from Doxorubicin
In order to determine whether preconditioning could protect a
cancer cell line against doxorubicin, we used HeLa cervical
cancer cells, which are sensitive to 2 μM doxorubicin. This
dose of doxorubicin caused an increase in cell death from 1.6
± 0.3% to 6.7 ± 1.7% after 18 h (Fig. 5a). sIPC did not protect
HeLa cells against this injury but paradoxically increased cell
death to 3.2 ± 2.6% in control and 10.4 ± 3.8% in those treated
with doxorubicin (n = 5) (Fig. 5a). Furthermore, sIPC did not
increase phosphorylation of Akt in HeLa cells (Fig. 5b).
Fig. 1 a The protective effect of simulated ischaemic preconditioning
(sIPC) against a range of doxorubicin (Dox) concentrations. Primary
adult rat cardiomyocytes were subject to 18 h Dox treatment at the indi-
cated concentrations, with or without preceding simulated ischaemic pre-
conditioning (sIPC). sIPC prevented the increase in cell death from 7.5 or
10 μMDox (** p < 0.01, *** p < 0.001 n = 5). b Inhibiting PI3K/Akt but
not MAPK/ERK1/2 eliminated sIPC-mediated protection against cell
death caused by 18 h exposure to 7.5 μM doxorubicin. Cells were treated
with LY294002 to inhibit PI3K/Akt or PD98059 to inhibitMAPK/ERK1/
2, throughout exposure to sIPC and Dox as in panel a. (*** p < 0.001 n =
5)
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Discussion
In this study, we show for the first time that the phenomenon
of ischaemic preconditioning directly protects isolated
cardiomyocytes against doxorubicin-induced cell death. This
protection appears to be dependent on PI3K/Akt, as confirmed
by first demonstrating that sIPC increases Akt phosphoryla-
tion in cells, and secondly that both Akt phosphorylation and
protection against Dox are abrogated by the presence of the
PI3K inhibitor LY294002. Although sIPC increased
MAPK/ERK1/2 phosphorylation, and this was abrogated by
PD98059, this inhibitor did not affect sIPC protection against
Dox.
Despite previous studies implicating ROS andmitochondri-
al damage in doxorubicin cardiotoxicity, thesemechanisms did
not appear to be involved in cardiotoxicity in our experimental
model, leading us to conclude sIPC-mediated protection from
doxorubicin-cardiotoxicity, we observed in our study, is
Fig. 2 aWestern blot analysis
demonstrated that sIPC activated
PI3K/Akt in cardiomyocytes, and
that LY294002 (LY) inhibited this
activation. Insulin, used as a pos-
itive control, strongly activated
PI3K/Akt, and this was decreased
by LY294002 treatment (n = 3). b
Western blot analyses for
MAPK/ERK1/2 similarly re-
vealed increased phosphorylation
in response to sIPC and to insulin
respectively, which was abrogat-
ed by treatment with PD98059
(n = 3)
Fig. 3 a A ROS scavenger
(NAC) did not affect Dox-
induced cardiomyocyte-death.
Cardiomyocytes were exposed to
18 h 7.5 μM Dox or 1 μM H2O2
in the presence or absence of
7.5 μM NAC, prior to analysis of
cell death. NAC rescued
cardiomyocytes from H2O2 tox-
icity, but had no effect on Dox-
induced death (n = 3, ** p < 0.01,
*** p < 0.001)
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independent of these pathways. Importantly, sIPC did not pro-
tect HeLa cancer cells from doxorubicin-induced death.
Doxorubicin has previously been shown to be toxic to
cardiomyocytes in a number of different models including neo-
natal rat ventricular myocytes, immortalised cardiomyoblasts
and cardiomyocyte-derived cell-lines [24, 25]. Treatment pro-
tocols and experimental design differ among the described
models, and doses ranged from those within the physiological
steady-state concentrations (in the range of 0.5–2 μM), to
supraphysiological concentrations up to 27 μM [26]. For
Fig. 4 a Exposure to doxorubicin
did not alter the sensitivity of the
mPTP to oxidative stress.
Cardiomyocytes were exposed to
1 μM CsA or 7.5 μM Dox for
18 h, before loading with a photo-
sensitising concentration of 3 μM
TMRM and subjecting cells to
laser-induced oxidative stress.
The time to mPTP opening was
measured and was significantly
increased by CsA in control cells
(CsA) but not in those cells that
had been exposed to Doxorubin
(Dox + CsA) (p < 0.05, n = 7). b
1 μM CsA did not protect
cardiomyocytes against exposure
to 18 h 7.5 μM Dox. Cell death
was measured at the end of 18 h
with vehicle (Con) or Dox
(p < 0.05, n = 5)
Fig. 5 a 2 μM doxorubicin (Dox)
increased cell death in HeLa can-
cer cells significantly, but pre-
conditioning did not protect them
(n = 5). b Akt was not phosphor-
ylated in response to sIPC in
HeLa cells
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comparison, the peak plasma concentration is typically in the
range of 5 μM in humans [1]. In our study, we used primary
adult rat ventricular myocytes to investigate doxorubicin-
induced injury. Since these are non-dividing terminally differ-
entiated cells, the model more accurately replicates a mature
cardiomyocyte at risk of doxorubicin-injury in comparison to a
dividing cell-line model (which may be tumour-derived) or an
undifferentiated neonatal rat ventricular myocyte model. Of
note, we investigated cardiomyocyte death in terminally differ-
entiated adult isolated rat cardiomyocytes in response to a range
of concentrations of doxorubicin, and an increase in cell death
was noted at, and above, peak plasma concentrations, which
became statistically significant from 7.5μM.We therefore used
this concentration in subsequent experiments.
When administered to an isolated, perfused rat heart, a
related anthracycline, epirubicin, decreased left ventricular de-
veloped pressure (LVDP) within 20 min. IPC was able to
decrease the damaging effect of epirubicin [16], but part of
this improvement in cardiac function might conceivably be
due to protection of the vasculature [27]. The present study
demonstrates that IPC can directly protect cardiomyocytes
against anthracycline cardiotoxicity.
Doxorubicin is known to modulate the PI3K/Akt and the
MAPK/ERK1/2 signalling pathways itself and may contribute
to its cardiotoxicity. In in vivo rodent models, after an initial
peak in MAPK/ERK1/2 phosphorylation during the first few
hours after doxorubicin administration, MAPK/ERK1/2 phos-
phorylation declines for weeks after the cessation of dosing.
This decline is paralleled by lower levels of ERK1/2 mRNA
and is accompanied by symptomatic heart failure [7].
Interestingly, in an acute isolated heart model, doxorubicin
was found to increase the phosphorylation of Akt and Erk1/2
when applied during the reperfusion phase after ischaemia
[28]. In neonatal rat cardiomyocytes, Zhu et al. observed an
induction of apoptosis with doxorubicin when ERK1/2 was
selectively inhibited [9]. Conversely, activation of the
MAPK/ERK1/2 signalling pathway has been suggested to be
a key-mediator of the protective effect seen with, for example,
the fatty acid oleylethanolamide against doxorubicin toxicity
[8]. Since both the PI3K/Akt andMAPK/ERK1/2 cascades are
known to be activated by IPC and exert a cardioprotective
effect in the acute setting, we explored if sIPC could protect
against the cardiotoxicity induced by this drug. Consistent with
our hypothesis, sIPC protected cardiomyocytes against a
cardiotoxic dose of doxorubicin. Specific inhibition of PI3K/
Akt or MAPK/ERK1/2 revealed this protective effect to be
dependent on the PI3K/Akt and independent of
MAPK/ERK1/2. Our data therefore clarifies the role of signal-
ling cascades of the RISK pathway that may hold protective
potential against doxorubicin cardiotoxicity. Interestingly, a
previous study has suggested that preconditioning using mor-
phine is able to confer cardioprotection in doxorubicin-induced
failing rat hearts via an ERK/GSK-3beta pathway independent
of PI3K/Akt [29], which suggests that there may be multiple
routes to cardioprotection against anthracyclines.
The mechanism by which PI3K/Akt protected cells against
doxorubicin is unclear. PI3K/Akt is known to protect against
ischemia-reperfusion injury by reducing ROS and decreasing
mPTP opening [23, 30]. Given that ROS have been implicated
in anthracycline cardiotoxicity [3, 31], we considered the pos-
sibility that PI3K/Akt protected cardiomyocytes by targeting
ROS. However, in our in vitro model, doxorubicin toxicity
was independent of ROS since a ROS scavenger failed to
rescue cardiomyocytes from doxorubicin-induced cell death.
This was despite the ROS scavenger protecting cells against
H2O2-induced death. Although ROS are established to be part
of the mechanism of doxorubicin-induced toxicity [31], ROS-
independent cell-death pathways have previously been impli-
cated in doxorubicin toxicity [32], and moreover, ROS scav-
engers have not exhibited any clinical benefit against doxoru-
bicin cardiotoxicity [4]. This raises the possibility that IPC can
protect against acute anthracycline cardiotoxicity by a mech-
anism independent of ROS.
Doxorubicin activates additional cell-death mechanisms,
including p53 induction and apoptosis secondary to DNA
damage [17]. Moreover, doxorubicin may also modulate pro-
teins involved in post-translational modifications such as his-
tone deacetylases [33] and thereby influence apoptotic path-
ways [18] as well as key homeostatic cellular pathways such
as autophagy [34]. Other pathways that have been suggested
to mediate doxorubicin-induced cardiomyocyte death include
inhibition of the mitochondrial respiratory chain and mito-
chondrial biogenesis pathways [35]. Doxorubicin-induced
cardiotoxicity is therefore likely to be a complexmultifactorial
process, and IPC may potentially impinge upon any, or all, of
these different pathways.
We observed no significant change in the mitochondrial
transmembrane potential after up to 24 h treatment with doxo-
rubicin. We further observed no difference in the sensitivity of
the mPTP between control group and doxorubicin-treated
cardiomyocytes. Surprisingly, cyclosporine A, a known inhib-
itor of the mPTP, was ineffective in preventing mPTP opening
in doxorubicin-treated cardiomyocytes. These results differ
from observations reported by other groups, both in in vitro
and ex vivo. For example, Fisher et al. reported a fall inΔΨm
in cultured adult mouse ventricular myocytes using the JC-1
dye following 18 h incubation with 1 μM doxorubicin [36].
Similarly, Zhang et al. isolated murine cardiomyocytes 72 h
after a large bolus dose of 25 mg/kg doxorubicin intraperito-
neally, and using JC-1, they observed a decrease inΔψm. [37].
A possible explanation for these different observations is that
we used TMRM rather than JC-1to measureΔΨm. Aggregate
(i.e. red) JC-1 fluorescence is highly sensitive to probe loading
concentrations and loading times and may change indepen-
dently of Δψm under some circumstances [38]. Using a sim-
ilar, laser-induced ROS model to ours, Gharanei et al. found
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that CsA was able to protect cardiomyocytes against mPTP
opening in the presence of 1 μM doxorubicin. However, pri-
mary adult rat cardiomyocytes were treated with doxorubicin
for only 10 min [28], in contrast to our 18-h treatment.
Similarly, Montaigne et al. measured the epicardial fluores-
cence of mitochondrial dye JC-1 in isolated perfused rat hearts
following 60min of 1 μMdoxorubicin infusion and found the
mitochondrial transmembrane potential dissipated in a time-
dependent manner [39].
Importantly, sIPCwas ineffective at protecting a cancer cell
line against doxorubicin injury in vitro, possibly because it did
not activate the cyto-protective PI3K/Akt pathway. This sug-
gests that it may be possible to use a preconditioning stimulus
to protect the heart from damage, without concomitantly
protecting the tumour being targeted for destruction.
Doxorubicin has been described variously as capable of
inflicting necrotic as well as apoptotic cardiomyocyte-death
[18]. A potential limitation of our study is that we measured
total cell-death as a marker of doxorubicin-induced cardiomyo-
cyte toxicity, without delineating the individual contributions of
each death pathway. A further limitation is the relatively high
dose of doxorubicin used, which was necessary to reveal car-
diomyocyte injury within the 18-h time period. Further studies
will be necessary to confirm that similar results are obtained
in vivo. The response of cancer cells to doxorubicin may be
altered in vivo, and therefore future experiments will be neces-
sary to confirm that IPC does not cause increased survival of
cancer cells in vivo. Finally, we recognise the possibility that
further replicates may reveal differences we were unable to
detect in our Western Blot and ROS scavenger experiments.
Conclusions and Future Directions
We show that the phenomenon of preconditioning protects
cardiomyocytes from doxorubicin cardiotoxicity in vitro.
This protection is mediated via the PI3K/Akt component of
the RISK pathway. The toxicity of doxorubicin appears inde-
pendent of ROS production and independent of induction of
the mPTP. However, we have not yet determined the precise
molecular target of the RISK pathway in protecting the
myocytes against doxorubicin-mediated cardiomyocyte
death. The protective potential of IPC may be further explored
in ex vivo and in vivo animal models.
Given that ischemic preconditioning is an invasive procedure,
it is not feasible to administer it to patients undergoing
anthracycline treatment. However, it is well established that
RISK pathway activation and cardioprotection is also elicited
by the application of a preconditioning stimulus to an organ or
limb remote from the heart [10]. This intervention, called remote
ischemic preconditioning (RIPC), reduces ischemia-reperfusion
(IR) injury and decreases peak troponin levels in patients under-
going thrombolysis for ST-elevation myocardial infarction [40].
Future studies will be important to investigate whether RIPC
may be effective against anthracycline cardiotoxicity. Indeed,
the Effect of Remote Ischaemic Conditioning in Oncology
(ERIC-ONC) trial (clinicaltrials.gov NCT 02471885) aims to
determine whether RIPC is cardioprotective in adult oncology
patients undergoing anthracycline-based chemotherapy treat-
ment [41]. It will be important to confirm that RIPC does not
provide a survival advantage to the tumour in situ.
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